CTOs on the Move

Bellicum

www.bellicum.com

 
Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.bellicum.com
  • 2130 West Holcombe Boulevard Suite 800
    Houston, TX USA 77030
  • Phone: 832.384.1100

Executives

Name Title Contact Details

Similar Companies

Kowa Pharmaceuticals America

Kowa Pharmaceuticals America is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenRx Pharmacy

Welcome to GenRx Pharmacy in Scottsdale, AZ. Visit our website for our location, information and new patient sign ups.

PCA Pharmacy

PCA Pharmacy is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Perlan Therapeutics Inc

Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia